TY - JOUR
T1 - Butenafine 1% cream in the treatment of tinea cruris
T2 - A multicenter, vehicle-controlled, double-blind trial
AU - Lesher, Jr
AU - Babel, D. E.
AU - Stewart, D. M.
AU - Jones, T. M.
AU - Kaminester, L.
AU - Goldman, M.
AU - Weintraub, J. S.
PY - 1997
Y1 - 1997
N2 - Background: Butenafine hydrochloride, a potent antifungal agent related to the allylamines, has been used in Japan for treating various cutaneous mycoses including tinea cruris.Objective: We compared the safety and efficacy of butenafine hydrochloride and its vehicle when used once daily for 2 weeks to treat tinea cruris. Methods: Patients (n = 93) with tinea cruris and a positive potassium hydroxide examination and mycologic culture were enrolled. Of the 76 patients assessed for efficacy, 37 applied butenafine and 39 applied vehicle once daily for 2 weeks. Assessments were made at the end of the 2-week treatment period and 4 weeks after the end of treatment. Results: Patients in the butenafine group had a higher mycologic cure rate by day 7 (66% vs 13%, p < 0.0001), with marked improvement 4 weeks after the end of treatment (81% vs 13%, p < 0.0001). They also had a higher rate of effective treatment at day 7 (29% vs 5%, p < 0.01) and at 4 weeks after treatment (73% vs 5%, < 0.0001). Adverse events definitely related to butenafine treatment were limited to one case of burning sensation after application. Conclusion: Butenafine applied once daily for 2 weeks is effective in treating tinea cruris. The proportion of patients cured increased between the end of treatment and 4 weeks after treatment.
AB - Background: Butenafine hydrochloride, a potent antifungal agent related to the allylamines, has been used in Japan for treating various cutaneous mycoses including tinea cruris.Objective: We compared the safety and efficacy of butenafine hydrochloride and its vehicle when used once daily for 2 weeks to treat tinea cruris. Methods: Patients (n = 93) with tinea cruris and a positive potassium hydroxide examination and mycologic culture were enrolled. Of the 76 patients assessed for efficacy, 37 applied butenafine and 39 applied vehicle once daily for 2 weeks. Assessments were made at the end of the 2-week treatment period and 4 weeks after the end of treatment. Results: Patients in the butenafine group had a higher mycologic cure rate by day 7 (66% vs 13%, p < 0.0001), with marked improvement 4 weeks after the end of treatment (81% vs 13%, p < 0.0001). They also had a higher rate of effective treatment at day 7 (29% vs 5%, p < 0.01) and at 4 weeks after treatment (73% vs 5%, < 0.0001). Adverse events definitely related to butenafine treatment were limited to one case of burning sensation after application. Conclusion: Butenafine applied once daily for 2 weeks is effective in treating tinea cruris. The proportion of patients cured increased between the end of treatment and 4 weeks after treatment.
UR - http://www.scopus.com/inward/record.url?scp=0031048086&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031048086&partnerID=8YFLogxK
U2 - 10.1016/S0190-9622(97)70318-9
DO - 10.1016/S0190-9622(97)70318-9
M3 - Article
C2 - 9039201
AN - SCOPUS:0031048086
SN - 0190-9622
VL - 36
SP - S20-S24
JO - Journal of the American Academy of Dermatology
JF - Journal of the American Academy of Dermatology
IS - 2
ER -